Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells.

Pineda DM, Rittenhouse DW, Valley CC, Cozzitorto JA, Burkhart RA, Leiby B, Winter JM, Weber MC, Londin ER, Rigoutsos I, Yeo CJ, Gorospe M, Witkiewicz AK, Sachs JN, Brody JR.

Cancer Biol Ther. 2012 Aug;13(10):946-55. doi: 10.4161/cbt.20952. Epub 2012 Aug 1.

2.

HuR's role in gemcitabine efficacy: an exception or opportunity?

Brody JR, Gonye GE.

Wiley Interdiscip Rev RNA. 2011 May-Jun;2(3):435-44. doi: 10.1002/wrna.62. Epub 2010 Nov 30. Review.

PMID:
21957028
3.

HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer.

Burkhart RA, Pineda DM, Chand SN, Romeo C, Londin ER, Karoly ED, Cozzitorto JA, Rigoutsos I, Yeo CJ, Brody JR, Winter JM.

RNA Biol. 2013 Aug;10(8):1312-23. doi: 10.4161/rna.25274. Epub 2013 Jun 13.

4.

HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.

Richards NG, Rittenhouse DW, Freydin B, Cozzitorto JA, Grenda D, Rui H, Gonye G, Kennedy EP, Yeo CJ, Brody JR, Witkiewicz AK.

Ann Surg. 2010 Sep;252(3):499-505; discussion 505-6. doi: 10.1097/SLA.0b013e3181f1fd44.

PMID:
20739850
5.

Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.

Jimbo M, Blanco FF, Huang YH, Telonis AG, Screnci BA, Cosma GL, Alexeev V, Gonye GE, Yeo CJ, Sawicki JA, Winter JM, Brody JR.

Oncotarget. 2015 Sep 29;6(29):27312-31. doi: 10.18632/oncotarget.4743.

6.

HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.

Jakstaite A, Maziukiene A, Silkuniene G, Kmieliute K, Gulbinas A, Dambrauskas Z.

World J Gastroenterol. 2015 Dec 14;21(46):13004-19. doi: 10.3748/wjg.v21.i46.13004.

7.

Caspase-mediated cleavage of RNA-binding protein HuR regulates c-Myc protein expression after hypoxic stress.

Talwar S, Jin J, Carroll B, Liu A, Gillespie MB, Palanisamy V.

J Biol Chem. 2011 Sep 16;286(37):32333-43. doi: 10.1074/jbc.M111.255927. Epub 2011 Jul 27.

8.

dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.

McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, Acosta Ade J, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR.

Cancer Biol Ther. 2014 Jun 1;15(6):688-98. doi: 10.4161/cbt.28413. Epub 2014 Mar 11.

9.

HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.

Romeo C, Weber MC, Zarei M, DeCicco D, Chand SN, Lobo AD, Winter JM, Sawicki JA, Sachs JN, Meisner-Kober N, Yeo CJ, Vadigepalli R, Tykocinski ML, Brody JR.

Mol Cancer Res. 2016 Jul;14(7):599-611. doi: 10.1158/1541-7786.MCR-15-0448. Epub 2016 Apr 6.

10.

The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.

Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Sawicki JA, Risbud MV, Witkiewicz AK, McCue PA, Jiang W, Rui H, Yeo CJ, Petricoin E, Winter JM, Brody JR.

Oncogene. 2016 May;35(19):2529-41. doi: 10.1038/onc.2015.325. Epub 2015 Sep 21.

PMID:
26387536
11.

TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.

Lemke J, Noack A, Adam D, Tchikov V, Bertsch U, Röder C, Schütze S, Wajant H, Kalthoff H, Trauzold A.

J Mol Med (Berl). 2010 Jul;88(7):729-40. doi: 10.1007/s00109-010-0619-0. Epub 2010 Mar 31. Erratum in: J Mol Med. 2011 Apr;89(4):423.

PMID:
20354842
12.

Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.

Jaganathan J, Petit JH, Lazio BE, Singh SK, Chin LS.

Neurosurg Focus. 2002 Sep 15;13(3):ecp1.

PMID:
15844877
13.

HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.

Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris ZA, Yeo CJ, Sawicki JA, Winter JM, Rigoutsos I, Yen TJ, Brody JR.

Cancer Res. 2014 Feb 15;74(4):1128-40. doi: 10.1158/0008-5472.CAN-13-1915.

14.

Attenuation of the ELAV1-like protein HuR sensitizes adenocarcinoma cells to the intrinsic apoptotic pathway by increasing the translation of caspase-2L.

Winkler C, Doller A, Imre G, Badawi A, Schmid T, Schulz S, Steinmeyer N, Pfeilschifter J, Rajalingam K, Eberhardt W.

Cell Death Dis. 2014 Jul 10;5:e1321. doi: 10.1038/cddis.2014.279.

15.

Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.

Kandasamy K, Kraft AS.

Mol Cancer Ther. 2008 May;7(5):1091-100. doi: 10.1158/1535-7163.MCT-07-2368.

16.

Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand.

Yasuda T, Yoshida T, Goda AE, Horinaka M, Yano K, Shiraishi T, Wakada M, Mizutani Y, Miki T, Sakai T.

Mol Cancer Res. 2008 Dec;6(12):1852-60. doi: 10.1158/1541-7786.MCR-08-0012.

17.

Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer.

Ozawa F, Friess H, Kleeff J, Xu ZW, Zimmermann A, Sheikh MS, Büchler MW.

Cancer Lett. 2001 Feb 10;163(1):71-81.

PMID:
11163110
18.

Importin β1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells.

Kojima Y, Nakayama M, Nishina T, Nakano H, Koyanagi M, Takeda K, Okumura K, Yagita H.

J Biol Chem. 2011 Dec 16;286(50):43383-93. doi: 10.1074/jbc.M111.309377. Epub 2011 Oct 21.

19.

HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.

Maréchal R, Van Laethem JL.

Expert Rev Anticancer Ther. 2009 Oct;9(10):1439-41. doi: 10.1586/era.09.119.

PMID:
19828005
20.

Supplemental Content

Support Center